Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalbavancin vs linezolid for treatment of acute bacterial infections of the skin.

Next Previous
X
Search
Trial Profile

Dalbavancin vs linezolid for treatment of acute bacterial infections of the skin.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalbavancin (Primary) ; Linezolid
  • Indications Gram-positive infections; Skin and soft tissue infections; Staphylococcal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Vicuron Pharmaceuticals

    • Most Recent Events

    • 05 Jun 2017 Results of retrospective analysis presented at the ASM Microbe 2017
    • 25 Apr 2017 Results of pooled analysis of clearance of bacteraemia data from four phase III studies and a phase II study including this study presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 30 Oct 2016 Pooled results of this and other 3 trial (DUR001-301, DUR001-302 and DUR001-303) presented at the IDWeek 2016

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top